177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Neuroblastoma
- Neuroblastoma Recurrent
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Younger than 1818 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04903899
- Collaborators
- Advanced Accelerator Applications
- Novartis
- Investigators
- Study Chair: Jakob Stenman, MD PhD Karolinska University Hospital